Moderna reports first quarter 2024 financial results and provides business updates

Reports first quarter revenues of $167 million, gaap net loss of $1.2 billion and gaap diluted eps of $(3.07) prepares for launches of rsv vaccine and spikevax® 2024-2025 formula; reaffirms 2024 expected product sales of approximately $4 billion initiated three new clinical studies evaluating moderna's investigational individualized neoantigen therapy in combination with merck's keytruda® for treatment of patients with bladder cancer, kidney cancer and cutaneous squamous cell carcinoma advanced three new vaccine programs (epstein-barr virus, varicella-zoster virus, norovirus) toward phase 3 clinical trials as announced at vaccines day investor event cambridge, ma / accesswire / may 2, 2024 / moderna, inc. (nasdaq:mrna) today reported financial results and provided business updates for the first quarter of 2024. "as we anticipate the launches of our spikevax 2024-2025 formula and rsv vaccine, we are exercising financial discipline and have intensified our focus on building and utilizing ai technologies to further streamline operations and enhance productivity," said stÉphane bancel, chief executive officer of moderna.
MRNA Ratings Summary
MRNA Quant Ranking